Congratulations to Tina B. Marvasti,🌟superstar🌟 alumnus of the U of T MD/PhD Program program, for this great achievement!

In patients w/ cardiovascular disease & overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8 mos. Full SELECT trial results: nej.md/465pj91 #AHA23 AHA Science

Gasps and applause at the opening AHA Late Breaking Science Session as this practice changing trial is presented, simultaneously published in NEJM and the New York Times reports “..standing room only” in a 5000 capacity hall. Robust analysis and discussion to follow - ask

A heart being shocked back into regular sinus rhythm from ventricular fibrillation @thebridgekau

Big shout out to the talented CCU team at the Toronto General Hospital for these creative Christmas decorations! Peter Munk Cardiac Centre toronto general hospital

I don’t know who needs to hear this, but, after HF consults all week, this PSA: SGLT2 inhibitors: 1. Don’t cause the UTI 2. Protect the kidneys (in stable CKD) 3. Are safe and effective in elderly pts 4. Rarely cause ketoacidosis when patient not insulin dependent Thank you 🙏

Among patients with obesity-related heart failure with preserved ejection fraction & type 2 diabetes, semaglutide produced greater reductions in symptoms, physical limitations & body weight than placebo at 1 year. Full STEP-HFpEF DM trial results: nej.md/3TPKpUC #ACC24

Presented today at #ACC24: In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone. Full trial results: nej.md/3xyXU3t

Original Article: Empagliflozin after Acute Myocardial Infarction (EMPACT-MI) nej.md/4cEb6EB Editorial: Decreasing the Risk of Heart Failure in a Changing Post–Myocardial Infarction Environment nej.md/3vFF1LK American College of Cardiology #ACC24

Deputy Prime Minister Chrystia Freeland announced a $2B investment in AI. Ahead of the announcement, she chatted with #TeamUHN's Heather Ross about Medly, an app that empowers patients with the tools to self-manage chronic conditions, like heart disease.⤵️ cpac.ca/headline-polit…

DanGer Shock is a positive trial, but not ECLS Shock. Is it because of the device, or the selected Population?. Let ´s discuss it…. 🧵

📄 #HotOffThePress! Read the latest #CJC Press Release: "Canadian Cardiovascular Society Issues Updated Guidelines to Assess Private and Commercial Drivers’ Fitness to Drive" 👉 onlinecjc.ca/content/latest… Full article 👉 onlinecjc.ca/article/S0828-…

A MAP of 65 mmHg does not mean adequate end organ perfusion

Cardiology humor at its finest 😂 H/T Preethi Pirlamarla MD

Aspirin for primary prevention of cardiovascular disease has been shown to cause more bleeding than benefit in randomized trials over the past 5 years. But it's still being taken by 1 of 3 older Americans. acpjournals.org/doi/full/10.73… Annals of Int Med Mohak Gupta Ashish Sarraju

Work hard, stay humble, be a good listener, have fun!

It’s always remarkable to witness the transition from V-tach to sinus rhythm with a bit of electricity. Heart coming back to normal beating ( rhythm 🎵 ) after cardiac surgery with electricity

Check out our manuscript where we discuss contemporary AI enabled wearable devices in cardiology and challenges facing their integration in healthcare. Thanks to the incredible mentorship of Yas Moayedi

🔥🔥🔥 An essential resource! Outstanding review on steroidal versus nonsteroidal MRA in HF. All trials, mechanisms, profiles. Andrew J Sauer MD Harriette Van Spall, MD MPH Andrew P. Ambrosy, MD #JACCHF JACC Journals jacc.org/doi/10.1016/j.…

In an era of global excellent #GDMT Usage: 📍RASi: 60% 📍B-blockers 86% 📍MRA 37% 📍ARNi 17% 📍SGLT2i 8% 🚨Triple/quadruple therapy was administered in 26% of hospitalizations, falling to 14% on discharge JACC Journals BiykemBozkurt 📎 rb.gy/clcfmm